Valneva, Pfizer Complete Recruitment For Phase 2 Trial Of Lyme Disease Vaccine Candidate

46
3
Favorite

Valneva, Pfizer Complete Recruitment For Phase 2 Trial Of Lyme Disease Vaccine Candidate

T-Reuters2021-07-19

Valneva SE:Valneva And Pfizer Complete Recruitment For Phase 2 Trial Of Lyme Disease Vaccine Candidate.Have Completed Recruitment For Phase 2 Trial, Vla15-221, Of Lyme Disease Vaccine Candidate, Vla15.Trial Builds On Previous Positive Phase 2 Trials And Includes Both Adult And Pediatric Participants.Main Safety And Immunogenicity Readout Will Be Performed Approximately One Month After Completion Of Primary Vaccination Schedule.Objective Of Trial Is To Show Safety And Immunogenicity Down To 5 Years Of Age And To Evaluate Optimal Vaccination Schedule For Use In Phase 3.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（3）

WangMeiLi
·2021-07-19
I think a good buy for vaccine and vitamin business til the end of this year!
Reply
Like
Report
doky
·2021-07-19
Good
Reply
1
Report
WealthyKitty
·2021-07-19
Tell me your opinion about this news...
Reply
2
Report
Fold Replies
- KVCGTan:
  ??
  2021-07-19
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2152636693?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-07-19 13:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2152636693","market":"us","top_or_hot":-1,"title":"Valneva, Pfizer Complete Recruitment For Phase 2 Trial Of Lyme Disease Vaccine Candidate","media":"T-Reuters","content":"<p><a href=\"https://laohu8.com/S/VNVLF\">Valneva SE</a>:Valneva And Pfizer Complete Recruitment For Phase 2 Trial Of Lyme Disease Vaccine Candidate.Have Completed Recruitment For Phase 2 Trial, Vla15-221, Of Lyme Disease Vaccine Candidate, Vla15.Trial Builds On Previous Positive Phase 2 Trials And Includes Both Adult And Pediatric Participants.Main Safety And Immunogenicity Readout Will Be Performed Approximately One Month After Completion Of Primary Vaccination Schedule.Objective Of Trial Is To Show Safety And Immunogenicity Down To 5 Years Of Age And To Evaluate Optimal Vaccination Schedule For Use In Phase 3.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Valneva, Pfizer Complete Recruitment For Phase 2 Trial Of Lyme Disease Vaccine Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nValneva, Pfizer Complete Recruitment For Phase 2 Trial Of Lyme Disease Vaccine Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n2021-07-19 13:02 北京时间&nbsp;&nbsp;&nbsp;<strong>T-Reuters</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Valneva SE:Valneva And Pfizer Complete Recruitment For Phase 2 Trial Of Lyme Disease Vaccine Candidate.Have Completed Recruitment For Phase 2 Trial, Vla15-221, Of Lyme Disease Vaccine Candidate, Vla15...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PFE","symbol_name":"辉瑞","start_time":0,"source_url":null,"article_id":"2152636693","we_media_id":"1086160438","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2152636693","pubTimestamp":1626670971,"sourceInfo":null,"weMediaInfo":{"media_name":"T-Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"summary":"Valneva SE:Valneva And Pfizer Complete Recruitment For Phase 2 Trial Of Lyme Disease Vaccine Candida","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PFE":"辉瑞"},"translate_title":"辉瑞瓦尔涅瓦完成莱姆病候选疫苗2期试验的招募","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":0.9,"VNVLF":0.9},"content_text":"Valneva SE:Valneva And Pfizer Complete Recruitment For Phase 2 Trial Of Lyme Disease Vaccine Candidate.Have Completed Recruitment For Phase 2 Trial, Vla15-221, Of Lyme Disease Vaccine Candidate, Vla15.Trial Builds On Previous Positive Phase 2 Trials And Includes Both Adult And Pediatric Participants.Main Safety And Immunogenicity Readout Will Be Performed Approximately One Month After Completion Of Primary Vaccination Schedule.Objective Of Trial Is To Show Safety And Immunogenicity Down To 5 Years Of Age And To Evaluate Optimal Vaccination Schedule For Use In Phase 3.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":173524700,"gmtCreate":1626672305800,"gmtModify":1703763101449,"author":{"id":"3586311073884660","authorId":"3586311073884660","name":"WangMeiLi","avatar":"https://static.tigerbbs.com/e42c8291e5033a92ae3c00b91053172b","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":3,"crmLevelSwitch":0,"idStr":"3586311073884660","authorIdStr":"3586311073884660"},"htmlText":"I think a good buy for vaccine and vitamin&nbsp;business til the end of this year!","listText":"I think a good buy for vaccine and vitamin&nbsp;business til the end of this year!","text":"I think a good buy for vaccine and vitamin business til the end of this year!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/173524700","repostId":2152636693,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":173525573,"gmtCreate":1626672186092,"gmtModify":1703763100286,"author":{"id":"3567308634822078","authorId":"3567308634822078","name":"doky","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3567308634822078","authorIdStr":"3567308634822078"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/173525573","repostId":2152636693,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":173522710,"gmtCreate":1626672051530,"gmtModify":1703763098305,"author":{"id":"3575024526885711","authorId":"3575024526885711","name":"WealthyKitty","avatar":"https://community-static.tradeup.com/news/c2f3d6e51cfe134f5ee2524525692a21","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":8,"crmLevelSwitch":1,"idStr":"3575024526885711","authorIdStr":"3575024526885711"},"htmlText":"Tell me your opinion about this news...","listText":"Tell me your opinion about this news...","text":"Tell me your opinion about this news...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/173522710","repostId":2152636693,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5259987,"gmtCreate":1626673683616,"gmtModify":1663231155443,"authorId":3570938362108330,"author":{"id":3570938362108330,"idStr":"3570938362108330","authorId":3570938362108330,"name":"KVCGTan","avatar":"https://static.tigerbbs.com/2126be6bc046089345232547cb51d38a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":173522710,"type":1,"supId":0,"prevId":0,"content":"??","text":"??","html":"??"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":46,"commentSize":3,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}